Browse News
Filter News
Found 115 articles
-
NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting
4/18/2024
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense") announces the presentation of data from the Company's PARADIGM Phase 2b study of PrimeC during an Emerging Science session (equivalent to Late Breaker) at the American Academy of Neurology Annual Meeting, which validates the previously announced topline data.
-
NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024
4/12/2024
NeuroSense Therapeutics Ltd. announces lead author Merit Cudkowicz, Chair of Neurology at Massachusetts General Hospital, and Julieanne Dorn Professor of Neurology at Harvard Medical School, will be presenting data from the PARADIGM Phase 2 study of PrimeC during an Emerging Science session (equivalent to Late Breaker) at the American Academy of Neurology Annual Meeting.
-
NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics
4/9/2024
Lonza (SIX: LONN), a global development and manufacturing partner to the pharma, biotech and nutrition industries, and NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for amyotrophic lateral sclerosis (ALS) and other severe neurodegenerative diseases.
-
NeuroSense Announces Year End 2023 Financial Results and Provides Business Update
4/5/2024
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, today reported its financial results for the year ended December 31, 2023 and provides a business update.
-
NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial
2/21/2024
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today reports additional positive data from its six-month double-blind Phase 2b PARADIGM trial of NeuroSense's lead drug candidate PrimeC for the treatment of amyotrophic lateral sclerosis ("ALS").
-
NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule
2/7/2024
NeuroSense Therapeutics Ltd. announced that it has received notice from The Nasdaq Stock Market LLC informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550 for continued listing.
-
NeuroSense Recaps Positive 2023 Achievements Including Statistically Significant Slowing of Disease Progression in Phase 2b ALS Trial of PrimeC and Highlights Anticipated 2024 Catalysts
1/9/2024
NeuroSense Therapeutics Ltd. shares a review of important clinical achievements in 2023 and provides a road map for anticipated catalysts in 2024.
-
NeuroSense Reports New Data: Statistically Significant Clinical Efficacy in Phase 2b ALS Trial
12/14/2023
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today reported additional positive efficacy data from further evaluation of its Phase 2b trial (PARADIGM) with NeuroSense's lead drug candidate for amyotrophic lateral sclerosis ("ALS"), PrimeC.
-
NeuroSense's Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints
12/5/2023
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today reported that it met its primary safety and tolerability endpoints and achieved secondary clinical efficacy endpoints in the top-line results of its randomized, placebo-controlled, double-blind segment the Company's Phase 2b amyotrophic lateral sclerosis ("ALS") trial of PrimeC ("PARADIGM").
-
NeuroSense to Report Phase 2b ALS Topline Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints on December 5, 2023
12/4/2023
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for neurodegenerative diseases, today announced it will report new data from the randomized, placebo-controlled, double-blind segment of its ongoing Phase 2b amyotrophic lateral sclerosis (ALS) trial (PARADIGM) of its lead drug candidate PrimeC.
-
NeuroSense Announces Third Quarter 2023 Financial Results and Provides Business Update
11/28/2023
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today reported its financial results for the nine months ended September 30, 2023 and provided a business update.
-
NeuroSense Receives U.S. FDA Confirmation of CMC Strategy for PrimeC in Preparation for Pivotal Phase 3 in ALS and Commercial Readiness
11/13/2023
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced it has concluded a successful Type D meeting with the U.S. Food and Drug Administration (FDA) for PrimeC in the treatment of amyotrophic lateral sclerosis (ALS).
-
NeuroSense Completes Dosing of Last Patient in the Double-Blind Segment of Phase 2b ALS Trial: Topline Clinical Efficacy Results Expected December 2023
11/6/2023
NeuroSense Therapeutics Ltd. today announced it has completed dosing of the last patient in the double-blind segment of its Phase 2b amyotrophic lateral sclerosis (ALS) trial of PrimeC (PARADIGM).
-
NeuroSense Therapeutics to Participate in BIO-Europe Fall
11/1/2023
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced its Chief Medical Officer Dr. Ferenc Tracik will participate in the 29th annual BIO-Europe Fall partnering conference on November 6-8, 2023 in Munich, Germany.
-
NeuroSense CEO Provides Q3 2023 Update
10/17/2023
NeuroSense Therapeutics Ltd., a company developing treatments for severe neurodegenerative diseases, provided an update from its CEO, Alon Ben-Noon, on the Company's clinical and operational developments during and immediately following the third quarter of 2023.
-
NeuroSense's PrimeC Demonstrates Outstanding Effect on ALS Survival in Innovative iPSC Model
10/4/2023
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense") today announced the results of a non-sponsored in vitro study of PrimeC in amyotrophic lateral sclerosis (ALS) conducted by Dr. Justin Ichida, PhD at the University of Southern California's (USC) Stem Cell Ichida Lab, part of the Eli and Edythe Broad CIRM Center for Regenerative Medicine and Stem Cell Research at USC.
-
NeuroSense Ends its At-The-Market Equity Offering Program: Company is Fully Funded Beyond Clinical Phase 2b ALS Results
10/2/2023
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced it has terminated its previously established "at-the-market" ("ATM") equity offering program.
-
Editas Medicine Strengthens Executive Leadership Team with Appointment of Caren Deardorf as Chief Commercial and Strategy Officer
9/25/2023
Editas Medicine, Inc., a clinical-stage genome editing company, announced the appointment of Caren Deardorf as the Company’s first Chief Commercial and Strategy Officer.
-
European Medicines Agency Grants NeuroSense SME Status
9/20/2023
NeuroSense Therapeutics Ltd. announced that it has opened an EU Office as well as been granted the Small and Medium-Sized Enterprise status by the European Medicines Agency, which offers significant benefits leading up to and following drug regulatory approval.
-
NeuroSense Granted Patents in Europe, Japan, and Israel for its ALS Drug PrimeC
9/19/2023
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced that the European, Japan, and Israel Patent Offices have granted the Company a key patent relating to "Compositions comprising an anti-inflammatory drug and a dicer activator for use in treatment of neuronal diseases."